Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 855,000 | 2,768,000 | 2,263,000 | 1,345,000 | 765,000 |
| Depreciation Amortization | 519,000 | 1,069,000 | 737,000 | 490,000 | 266,000 |
| Income taxes - deferred | -406,000 | -500,000 | -222,000 | -174,000 | -50,000 |
| Accounts receivable | N/A | 701,000 | -10,000 | -2,000 | N/A |
| Other Working Capital | -277,000 | 594,000 | -17,000 | 588,000 | -23,000 |
| Other Operating Activity | 65,000 | -498,000 | -45,000 | -23,000 | -58,000 |
| Operating Cash Flow | $756,000 | $4,134,000 | $2,706,000 | $2,224,000 | $900,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -148,000 | -774,000 | -561,000 | -319,000 | -149,000 |
| Net Acquisitions | N/A | -6,561,000 | -1,360,000 | -446,000 | -446,000 |
| Purchase Of Investment | -8,000 | -217,000 | -142,000 | -117,000 | -71,000 |
| Other Investing Activity | -38,000 | -49,000 | -47,000 | -34,000 | -10,000 |
| Investing Cash Flow | $-194,000 | $-7,601,000 | $-2,110,000 | $-916,000 | $-676,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 143,000 | -124,000 | 905,000 | -511,000 | -102,000 |
| Debt Issued | N/A | 6,723,000 | 749,000 | 749,000 | 748,000 |
| Debt Repayment | -61,000 | -1,565,000 | -1,034,000 | -826,000 | -839,000 |
| Common Stock Issued | 12,000 | 71,000 | 55,000 | 31,000 | 23,000 |
| Common Stock Repurchased | -533,000 | -899,000 | -749,000 | -495,000 | -400,000 |
| Dividend Paid | -174,000 | -800,000 | -610,000 | -406,000 | -203,000 |
| Other Financing Activity | 0 | -70,000 | -72,000 | 4,000 | 3,000 |
| Financing Cash Flow | $-613,000 | $3,336,000 | $-756,000 | $-1,454,000 | $-770,000 |
| Exchange Rate Effect | 17,000 | -21,000 | -3,000 | 37,000 | 19,000 |
| Beginning Cash Position | 1,096,000 | 1,248,000 | 1,248,000 | 1,248,000 | 1,248,000 |
| End Cash Position | 1,062,000 | 1,096,000 | 1,085,000 | 1,139,000 | 721,000 |
| Net Cash Flow | $-34,000 | $-152,000 | $-163,000 | $-109,000 | $-527,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 756,000 | 4,134,000 | 2,706,000 | 2,224,000 | 900,000 |
| Capital Expenditure | -274,000 | -1,053,000 | -736,000 | -460,000 | -234,000 |
| Free Cash Flow | 482,000 | 3,081,000 | 1,970,000 | 1,764,000 | 666,000 |